Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease? Fatih Albayrak; Mustafa Gür; Ahmet Karata¿; Süleyman Serdar Koca; Bünyamin K¿sac¿k;

Secukinumab como tratamiento biológico en la artritis psoriásica en práctica clínica real José A. Pinto Tasende; Francisco J. Maceiras Pan; José A. Mosquera Martínez; Luis Fernández Dominguez; Blanca Correa Rey; Carlos García Porrúa;

Changes in immature granulocyte levels and their association with disease activation following biologic therapy in patients with ankylosing spondylitis Burak Okyar; Servet Yüce; ¿brahim Halil Bilen; Bekir Torun; ¿lyas Öztürk; Gözde Y¿ld¿r¿m Çetin;